-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $19

Benzinga · 01/06/2023 06:28
HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $25 to $19.